Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium-177 octreotate with capecitabine and temozolomide for neuroendocrine tumours
ACTRN12610000440022Phase 2Recruiting
- Sponsor
- Fremantle Hospital
- Start
- Jul 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate, capecitabine and temozolomide in neuroendocrine tumour (NET) and apudoma (NET), sponsored by Fremantle Hospital. Primary endpoints: Objective response rate / progression-free assessment and Progression-free survival. Started Jul 2006; status: recruiting.
02
Drugs
lutetium Lu 177 dotatatecapecitabinetemozolomide
03
Conditions
neuroendocrine tumour (NET)apudoma (NET)
Beyond the preview
Go deeper on ACTRN12610000440022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000440022.